Skip to main content

TRANCE/TNFSF11/RANK L Antibody (IK22-5) - Chimeric - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-81123

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-81123-0.025mg
NBP2-81123-0.2mg

Key Product Details

Species Reactivity

Validated:

Mouse

Applications

Flow Cytometry, Immunohistochemistry, Neutralization

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Kappa Clone # IK22-5

Format

Azide and BSA Free

Concentration

1 mg/ml

Product Summary

Immunogen

Thus antibody was raised by immunising an SD rat with murine TRANCE/TNFSF11/RANK L-transfected baby hamster kidney cells.

Specificity

This antibody is specific for murine TRANCE/TNFSF11/RANK L.

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG Kappa

Applications

Application
Recommended Usage

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Neutralization

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. This antibody has been used in immunohistochemical analysis of frozen Peyer's patch tissue sections (Kobayashi et al, 2013). It has also been used in flow cytometric analysis of RANKL cell surface expression by Th1 and Th17 cells (Nakae et al, 2007), RANKL-transfected human embryonic kidney cells (Miyahira et al, 2003) and murine T hybridoma 2B4.11 cells (Fionda et al, 2007). Additionally, this RANKL-neutralising antibody has been used to assess the effects of RANKL inhibition on myoepithelial cell proliferation in mammary organoid culture (Haslam et al, 2008). Treatment of collagen-induced arthritis (CIA) mice with this antibody has been shown to reduce bone loss at the site of inflammation (Kamijo et al, 2006), while administration to C57BL/6J mice induced transient tibia and skull bone growth arrest and irreversible blockage of tooth eruption (Lezot et al, 2015).
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS

Format

Azide and BSA Free

Preservative

0.02% Proclin 300

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.

Background: TRANCE/TNFSF11/RANK L

TRANCE/OPGL/RANKL/ODF is a recently identified member of tumor necrosis factor family. TRANCE (TNF-related activation-induced cytokine receptor) or RANKL {receptor activator of NF-kB (RANK) ligand} has been implicated in interactions between T cells and dendritic cells (1-2). RANK ligand (RANKL/TRANCE) binds to RANK on dendritic cells, upregulates the expression of anti-apoptotic protein BcL-XL suggesting a role in dendritic cell survival (2). TRANCE/RANKL is also important in T and B-cell maturation (3). As OPGL/ODF (Osteoprotegerin Ligand/Osteoclast differentiation factor), the same protein can both activate mature osteoclasts and mediate osteoclastogenesis (4). OPGL/TRANCE deficient mice show severe osteoporesis and complete absence of osteoclasts as a result of lack of osteogenesis (3).

Long Name

TNF-related Activation-induced Cytokine

Alternate Names

CD254, ODF, OPGL, RANK L, RANKL, TNFSF11

Gene Symbol

TNFSF11

Additional TRANCE/TNFSF11/RANK L Products

Product Documents

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...